However, the increasing number of germline TP53 variants detected in cancer patients without familial history, the incomplete and variable penetrance of the variants, the observation that only a fraction of variant carriers have access to this protocol, especially in US, lead us to propose a more stratified protocol in the framework of the European Reference Network GENTURIS, in order to help decision making [14]. Here, TP53 is linked to cancer.